Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

7.12

Today's Change

-0.34 (4.55%)

Day's Change

7.11 - 7.68

Trading Volume

588,697

Overview

Market Cap

2 Billion

Shares Outstanding

320 Million

Avg Volume

1,960,768

Avg Price (50 Days)

7.46

Avg Price (200 Days)

5.09

PE Ratio

-44.50

EPS

-0.16

Earnings Announcement

22-Nov-2024

Previous Close

7.46

Open

7.46

Day's Range

7.11 - 7.68

Year Range

1.175 - 8.975

Trading Volume

588,697

Price Change Highlight

1 Day Change

-4.56%

5 Day Change

-3.65%

1 Month Change

2.15%

3 Month Change

15.58%

6 Month Change

82.56%

Ytd Change

237.44%

1 Year Change

524.56%

3 Year Change

571.70%

5 Year Change

374.67%

10 Year Change

374.67%

Max Change

374.67%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment